Concepedia

Changes in the QTc interval after administration of flecainide acetate, with and without coadministered Paroxetine, in Relation to Cytochrome P450 2D6 Genotype: Data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects

Kyoung Soo Lim, In‐Jin Jang, Bo‐Hyung Kim, Jae Woo Kim, Ji‐Young Jeon, SoJeong Yi, SoYoung Eum, Joo‐Youn Cho, Sang‐Goo Shin, Kyung‐Sang Yu

Clinical Therapeutics · 2010 · 39 citations · 14 references

DOI

Concepts

References

14

Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram

Joel Morganroth, Leonard N. Horowitz · The American Journal of Cardiology · 1984 · 280 citations

, , +14

IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE

Karthik Venkatakrishnan, R. Scott Obach · Drug Metabolism and Disposition · 2005 · 121 citations

, , +17

Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone

Christian Funck‐Brentano, Laurent Becquemont, Heyo K. Kroemer et al. · Clinical Pharmacology & Therapeutics · 1994 · 77 citations

, , +16

Sample Size, Power Calculations, and Their Implications for the Cost of Thorough Studies of Drug Induced QT Interval Prolongation

Marek Malik, Katerina Hnatkova, Velislav N. Batchvarov et al. · Pacing and Clinical Electrophysiology · 2004 · 75 citations

, , +15

Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Gerd Mikus, Christine Fischer, Rita Hertrampf et al. · British Journal of Clinical Pharmacology · 1989 · 56 citations · Full text

, , +13